Notably, among JAKis approved for the treatment of RA, baricitinib uniquely demonstrated high affinity for AAK1, BIKE, and GAK, whereas tofacitinib and upadacitinib did not demonstrate high affinity for these kinases (Fig 2B). This evidence concerns the gene BMP2K and rheumatoid arthritis.